Epilepsy and bone health in adults.
ABSTRACT Adults taking antiepileptic drugs (AEDs) have an augmented risk for osteopenia and osteoporosis because of abnormalities of bone metabolism associated with AEDs. The increased fracture rates that have been described among patients with epilepsy may be related both to seizures and to AEDs. The hepatic enzyme-inducing AEDs phenytoin, phenobarbital, and primidone have the clearest association with decreased bone mineral density (BMD). Carbamazepine, also an enzyme-inducing drug, and valproate, an enzyme inhibitor, may also adversely affect bone, but further study is needed. Little information is available about specific effects of newer AEDs on bone. Physicians are insufficiently aware of the association between AEDs and bone disease; a survey found that fewer than one-third of neurologists routinely evaluated AED-treated patients for bone disease, and fewer than 10% prescribed prophylactic calcium and vitamin D. Physicians should counsel patients taking AEDs about good bone health practices, and evaluation of bone health by measuring BMD is warranted after 5 years of AED treatment or before treatment in postmenopausal women.
- SourceAvailable from: Lut Tamam[Show abstract] [Hide abstract]
ABSTRACT: Mood disorders are common and chronic disorders in general population. During acute episodes and chronic treatment of mood disorders, lithium and several antiepileptic drugs (i.e. valproic acid, carbamazepine and lamotrigine) are used as mood stabilizers. Many different adverse effects could be observed during the chronic course of these disorders due to long term drug treatment. Because of their rare prevalence and insufficient evaluation, some of these adverse effects could be missed by the physician. One of such adverse effects is the influence of mood stabilizers on bone metabolism. There is relatively scarce number of research about the influence of mood stabilizers on bone metabolism in literature. Since some of these drugs are also antiepileptic drugs (valproic acid, carbamazepine, lamotrigine), the studies conducted on this issue mainly involved epileptic patients in pediatric age group. The influence and the mechanism of action of these drugs on adult bone metabolism has not been yet clarified. Thus there is not any exact treatment algorithm that could be used among such patients. For all patients, risk and benefit ration of the drugs should be estimated and drugs should be used accordingly. In this paper, the relationship between mood stabilizer drug use and bone metabolism, the mechanism associated with the development of secondary osteoporosis, prevention of such adverse effects and treatment procedures have bben discussed and reviewed briefly.Bulletin of Clinical Psychopharmacology 01/2009; 19(4):305-311. · 0.37 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Introduction: Adverse drug effects and drug−drug interactions (DDIs) can be elicited by the activation of several nuclear receptors (NRs). Of the NRs that regulate expression of drug metabolizing enzymes and transporters and alter cellular processes, the most important are pregnane X receptor, constitutive androstane receptor and aryl hydrocarbon receptor. Screening for the activation of these receptors can be achieved during drug discovery by using various high-throughput analyses including ligand binding and transactivation assays. Areas covered: This review focuses on the importance of screening for NR activation during drug discovery and includes a discussion of the various assays to evaluate activation of NRs by xenobiotics. It also describes screening for species-specific NR activation to attenuate the use of animals in toxicology studies and to identify complications associated with drug metabolism and clearance that may occur during pharmacokinetic analyses. Expert opinion: Given the potential for adverse drug effects and DDIs during all phases of drug elimination, NR screening should occur early in drug discovery. Such screening could be used in structure–activity relationship studies to guide chemists in altering compound structures to eliminate the NR-binding and activation properties on priority compounds. Early screening can also reduce the risk of adverse drug effects, identify novel therapeutic agents and decrease the number of animals used in drug development. Overall, performing these types of assays described here could decrease drug development costs, alleviate the liability associated with drugs that activate NR and prevent unsafe drugs from entering the marketplace.Expert Opinion on Drug Discovery 06/2014; 9(6). · 3.47 Impact Factor
- Journal of Epilepsy and Clinical Neurophysiology 03/2006; 12(1):17-23.